 Home > Active Ingredient News > Drugs Articles > BioNTech's latest financial report: 4 clinical trials are aimed at Delta variants, and 15 anti-cancer therapies are in clinical development

BioNTech's latest financial report: 4 clinical trials are aimed at Delta variants, and 15 anti-cancer therapies are in clinical development

 Last Update: 2021-08-29
 Source: Internet
 Author: User

Tags

basic sex

flu shot reaction

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, BioNTech announced its financial report for the second quarter (Q2) of 2021

The latest research and development plan for the currently popular Delta variant has 15 anti-cancer therapies in the field of oncology under evaluation in 18 clinical trials

Research and development strategy for new crown variants

BioNTech said that in view of the continuous emergence of new crown variants, the company is already cooperating with Pfizer to establish the development, production and supervision of vaccine candidates for specific new crown variants

BioNTech and Pfizer have launched a phase 3 clinical trial involving 10,000 people to test the protective effect of the third dose of BNT162b2 at a dose of 30 μg in people over the age of 16 who have received two doses of the vaccine.

▲BioNTech's clinical development strategy for new crown variants (picture source: reference [2])

The safety and immunogenicity test of the third shot to enhance the vaccine has obtained preliminary results

For the wild type, the neutralization titer is increased by 5-8 times compared with the second dose of vaccine, and for the Delta variant, the neutralization titer is increased by 5-11 times

▲BNT162b2 enhanced vaccination resulted in a strong neutralization reaction (picture source: reference [2])

Create a new generation of cancer immunotherapy

In addition to further developing vaccines for infectious diseases based on mRNA technology, BioNTech is also committed to using mRNA technology to develop a new generation of cancer immunotherapy

The FixVac technology platform aims to use mRNA to express antigens shared in a variety of tumors.

▲Introduction to FixVac technology platform (picture source: reference [2])

The main therapy on this platform, BNT111, is an off-the-shelf therapeutic vaccine for the treatment of melanoma

BNT111 is an off-the-shelf therapeutic vaccine for the treatment of melanoma

▲BNT111 has shown gratifying results in phase 1 clinical trials (picture source: reference [2])

BNT113 is a therapeutic vaccine encoding HPV16 oncogenic proteins E6 and E7

BNT113 has the potential to increase the patient's response to immune checkpoint inhibitors and the duration of remission by stimulating an immune response against HPV16 protein

▲Introduction to BNT113 (picture source: reference [2])

In phase 1 clinical trials, BNT113 can stimulate antigen-specific CD4 and CD8 positive T cell responses

BNT113 can stimulate the response of antigen-specific CD4 and CD8 positive T cells

▲BNT113 stimulated antigen-specific T cell responses in phase 1 clinical trials (picture source: reference [2])

In addition, the personalized tumor neoantigen vaccine BNT122 developed by the company is also in phase 2 clinical development as an adjuvant therapy for patients with metastatic colorectal cancer

BioNTech's RiboCytokines technology platform is an innovative treatment model

RiboCytokines aims to overcome the limitations of traditional cytokine therapy, using liver-targeted lipid nanoparticles (LNP) to deliver cytokine-expressing mRNA, making somatic cells a "factory" for cytokine production

▲Introduction of RiboCytokines (picture source: reference [2])

The BNT151 developed under this platform is an mRNA encoding a variant of IL-2.

BNT151 is an mRNA encoding IL-2 variants.
Its design reduces the ability of IL-2 to bind to IL2Rα.
It is designed to activate effector T cells while avoiding the activation of regulatory T cells with immunosuppressive ability
.

The combination of BNT152+153 uses another strategy to achieve the same goal.
BNT152, which encodes IL-2, can simultaneously activate T cells with anti-cancer function and regulatory T cells with immunosuppressive function, while BNT153, which encodes IL-7, can make the effect.
While sex T cells are more sensitive to IL-2, they limit the function of regulatory T cells
.

Both RiboCytokines are currently being evaluated in phase 1 clinical trials for the treatment of solid tumors
.

Reference materials:

[1] BioNTech Announces Second Quarter 2021 Financial Results and Corporate Update.
Retrieved August 9.
2021.
from https://investors.
biontech.
de/news-releases/news-release-details/biontech-announces-second-quarter-2021 -financial-results-and

[2] Second Quarter 2021.
Corporate update and financial results.
Retrieved August 9.
2021.
from https://investors.
biontech.
de/static-files/02db321f-b4b5-4111-9227-83bbd6ffee33

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.